Mass cytometry analysis reveals a distinct immune environment in peritoneal fluid in endometriosis: a characterisation study.

Adaptive immunity CD69 Endometriosis Immune cells Innate immunity Mass cytometry Peripheral blood Peritoneal fluid

Journal

BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723

Informations de publication

Date de publication:
07 01 2020
Historique:
received: 24 07 2019
accepted: 19 11 2019
entrez: 8 1 2020
pubmed: 8 1 2020
medline: 21 10 2020
Statut: epublish

Résumé

Endometriosis is a gynaecological condition characterised by immune cell infiltration and distinct inflammatory signatures found in the peritoneal cavity. In this study, we aim to characterise the immune microenvironment in samples isolated from the peritoneal cavity in patients with endometriosis. We applied mass cytometry (CyTOF), a recently developed multiparameter single-cell technique, in order to characterise and quantify the immune cells found in peritoneal fluid and peripheral blood from endometriosis and control patients. Our results demonstrate the presence of more than 40 different distinct immune cell types within the peritoneal cavity. This suggests that there is a complex and highly heterogeneous inflammatory microenvironment underpinning the pathology of endometriosis. Stratification by clinical disease stages reveals a dynamic spectrum of cell signatures suggesting that adaptations in the inflammatory system occur due to the severity of the disease. Notably, among the inflammatory microenvironment in peritoneal fluid (PF), the presence of CD69 This study provides a systematic characterisation of the specific immune environment in the peritoneal cavity and identifies cell immune signatures associated with endometriosis. Overall, our results provide novel insights into the specific cell phenotypes governing inflammation in patients with endometriosis. This prospective study offers a useful resource for understanding disease pathology and opportunities for identifying therapeutic targets.

Sections du résumé

BACKGROUND
Endometriosis is a gynaecological condition characterised by immune cell infiltration and distinct inflammatory signatures found in the peritoneal cavity. In this study, we aim to characterise the immune microenvironment in samples isolated from the peritoneal cavity in patients with endometriosis.
METHODS
We applied mass cytometry (CyTOF), a recently developed multiparameter single-cell technique, in order to characterise and quantify the immune cells found in peritoneal fluid and peripheral blood from endometriosis and control patients.
RESULTS
Our results demonstrate the presence of more than 40 different distinct immune cell types within the peritoneal cavity. This suggests that there is a complex and highly heterogeneous inflammatory microenvironment underpinning the pathology of endometriosis. Stratification by clinical disease stages reveals a dynamic spectrum of cell signatures suggesting that adaptations in the inflammatory system occur due to the severity of the disease. Notably, among the inflammatory microenvironment in peritoneal fluid (PF), the presence of CD69
CONCLUSIONS
This study provides a systematic characterisation of the specific immune environment in the peritoneal cavity and identifies cell immune signatures associated with endometriosis. Overall, our results provide novel insights into the specific cell phenotypes governing inflammation in patients with endometriosis. This prospective study offers a useful resource for understanding disease pathology and opportunities for identifying therapeutic targets.

Identifiants

pubmed: 31907005
doi: 10.1186/s12916-019-1470-y
pii: 10.1186/s12916-019-1470-y
pmc: PMC6945609
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3

Subventions

Organisme : Arthritis Research UK
ID : 20522
Pays : United Kingdom

Références

Int J Gynaecol Obstet. 1993 Oct;43(1):45-50
pubmed: 7904954
Immunology. 2009 Apr;126(4):449-57
pubmed: 19278418
Biomed Res Int. 2015;2015:341308
pubmed: 26366410
Fertil Steril. 2001 Aug;76(2):223-31
pubmed: 11476764
J Clin Invest. 2003 Sep;112(6):872-82
pubmed: 12975472
Reprod Sci. 2014 Oct;21(10):1228-36
pubmed: 24594835
Stem Cells. 1994 Sep;12(5):456-65
pubmed: 7804122
BJOG. 2011 Jan;118(1):6-16
pubmed: 21083865
FASEB J. 2008 Feb;22(2):522-9
pubmed: 17873101
Hum Reprod Update. 2014 Sep-Oct;20(5):702-16
pubmed: 24676469
Hum Reprod. 1996 Aug;11(8):1736-40
pubmed: 8921125
Am J Pathol. 2009 Aug;175(2):547-56
pubmed: 19574425
Front Immunol. 2013 Jan 28;4:9
pubmed: 23372570
Cell Death Dis. 2014 Oct 02;5:e1436
pubmed: 25275597
Nat Biotechnol. 2013 Jun;31(6):545-52
pubmed: 23685480
Am J Respir Cell Mol Biol. 1999 Nov;21(5):547-54
pubmed: 10536111
Fertil Steril. 1994 Nov;62(5):1086-8
pubmed: 7926125
Hum Reprod. 2014 Oct 10;29(10):2176-89
pubmed: 25035432
Hum Reprod Update. 1998 Sep-Oct;4(5):741-51
pubmed: 10027629
Nature. 1999 Oct 14;401(6754):708-12
pubmed: 10537110
Immunol Cell Biol. 2014 Feb;92(2):133-8
pubmed: 24296810
F1000Prime Rep. 2014 Mar 03;6:13
pubmed: 24669294
J Immunol. 2002 Apr 1;168(7):3536-42
pubmed: 11907116
Am J Reprod Immunol. 2006 Apr;55(4):276-81
pubmed: 16533339
mBio. 2013 Jun 18;4(3):e00264-13
pubmed: 23781069
Anal Chem. 2009 Aug 15;81(16):6813-22
pubmed: 19601617
Nat Rev Immunol. 2014 Aug;14(8):571-8
pubmed: 25033907
Nat Methods. 2016 Jun;13(6):493-6
pubmed: 27183440
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
Minerva Ginecol. 2003 Aug;55(4):333-45
pubmed: 14581858
Fertil Steril. 1997 May;67(5):817-21
pubmed: 9130884
Immunology. 2006 Mar;117(3):289-300
pubmed: 16476048
Fertil Steril. 2001 Jan;75(1):1-10
pubmed: 11163805
Endocrinology. 2014 Dec;155(12):4986-99
pubmed: 25243856
Autoimmun Rev. 2012 Sep;11(11):806-14
pubmed: 22330229
J Immunol. 2011 Jul 1;187(1):164-71
pubmed: 21622859
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
Nat Rev Immunol. 2002 Mar;2(3):151-61
pubmed: 11913066
Sci Transl Med. 2014 Feb 5;6(222):222ra16
pubmed: 24500404
Brain. 2011 Feb;134(Pt 2):542-54
pubmed: 21216829
J Immunol Methods. 2014 Dec 15;415:1-5
pubmed: 25450003
Sci Rep. 2015 Sep 11;5:13886
pubmed: 26358827
Blood. 1991 Aug 15;78(4):1105-11
pubmed: 1907873
Hum Reprod. 2013 Jan;28(1):119-24
pubmed: 23019301
J Exp Med. 1993 Aug 1;178(2):669-74
pubmed: 7688031
Am J Pathol. 1927 Mar;3(2):93-110.43
pubmed: 19969738
Science. 2011 May 6;332(6030):687-96
pubmed: 21551058
Hum Reprod. 2009 Jul;24(7):1695-703
pubmed: 19321495
Autoimmun Rev. 2018 Oct;17(10):945-955
pubmed: 30107265
Immunity. 2014 Jul 17;41(1):14-20
pubmed: 25035950
Cell Rep. 2014 Nov 6;9(3):1075-88
pubmed: 25437561
Eur J Immunol. 2013 Nov;43(11):2797-809
pubmed: 24258910
J Assist Reprod Genet. 2010 Aug;27(8):441-7
pubmed: 20574791
J Immunol. 2014 Apr 1;192(7):3280-8
pubmed: 24610015
Nat Rev Immunol. 2012 Feb 17;12(3):191-200
pubmed: 22343568
J Immunol. 2005 Jul 1;175(1):342-9
pubmed: 15972667
J Immunol. 2009 Jan 1;182(1):111-20
pubmed: 19109141
Eur J Obstet Gynecol Reprod Biol. 2014 Aug;179:253
pubmed: 24890682
J Immunol. 1993 Sep 1;151(5):2426-35
pubmed: 7689607
Semin Reprod Med. 2003 May;21(2):243-54
pubmed: 12917793
Arch Gynecol Obstet. 2016 Sep;294(3):657-64
pubmed: 27358184
Fertil Steril. 1988 Aug;50(2):216-22
pubmed: 3294043
Minerva Endocrinol. 2012 Mar;37(1):75-92
pubmed: 22382616
J Exp Med. 2008 Aug 4;205(8):1903-16
pubmed: 18663128
Cell Mol Life Sci. 2015 Jun;72(12):2349-60
pubmed: 25715742
Nat Rev Immunol. 2005 Dec;5(12):953-64
pubmed: 16322748
J Immunol. 1991 Jun 15;146(12):4105-14
pubmed: 1710239
Reprod Biol Endocrinol. 2003 Dec 02;1:123
pubmed: 14651748
Hum Reprod. 1995 Mar;10(3):558-62
pubmed: 7782431

Auteurs

Manman Guo (M)

Botnar Research Centre, NIHR Biomedical Research Unit Oxford, Nuffield Department of Musculoskeletal Sciences, University of Oxford, Oxford, UK. manman.guo@ndorms.ox.ac.uk.

Cemsel Bafligil (C)

Botnar Research Centre, NIHR Biomedical Research Unit Oxford, Nuffield Department of Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Thomas Tapmeier (T)

Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK.

Carol Hubbard (C)

Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK.

Sanjiv Manek (S)

Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK.

Catherine Shang (C)

Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK.

Fernando O Martinez (FO)

Botnar Research Centre, NIHR Biomedical Research Unit Oxford, Nuffield Department of Musculoskeletal Sciences, University of Oxford, Oxford, UK.

Nicole Schmidt (N)

Bayer AG, Drug Discovery Pharmaceuticals, Gynecological Therapies, Müllerstr. 178, Berlin, Germany.

Maik Obendorf (M)

Bayer AG, Drug Discovery Pharmaceuticals, Gynecological Therapies, Müllerstr. 178, Berlin, Germany.

Holger Hess-Stumpp (H)

Bayer AG, Drug Discovery Pharmaceuticals, Gynecological Therapies, Müllerstr. 178, Berlin, Germany.

Thomas M Zollner (TM)

Bayer AG, Drug Discovery Pharmaceuticals, Gynecological Therapies, Müllerstr. 178, Berlin, Germany.

Stephen Kennedy (S)

Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK.

Christian M Becker (CM)

Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK.

Krina T Zondervan (KT)

Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK.
The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.

Adam P Cribbs (AP)

Botnar Research Centre, NIHR Biomedical Research Unit Oxford, Nuffield Department of Musculoskeletal Sciences, University of Oxford, Oxford, UK. adam.cribbs@ndorms.ox.ac.uk.

Udo Oppermann (U)

Botnar Research Centre, NIHR Biomedical Research Unit Oxford, Nuffield Department of Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Freiburg Institute for Advanced Studies (FRIAS), University of Freiburg, Freiburg im Breisgau, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH